Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myeloid, Acute 6Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Congenital Abnormalities 4Blast Crisis 4Unspecified Adult Solid Tumor, Protocol Specific 3Pancreatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Gliosarcoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Anemia, Refractory, with Excess of Blasts 2Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1

Interventions

tipifarnib 1penpulimab 1Sorafenib 1Rifampin 1Itraconazole 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Malignant Neoplasm × tipifarnib × Clear all
NCT00244972 2017-04-27

Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
74 enrolled
Other neoplasm

Advanced Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡